IAS 2023: Pharmacists
Integrating New Data on HIV Adverse Events From IAS 2023: Pharmacist Perspectives

Released: September 15, 2023

Brooke Bates
Brooke Bates, PharmD, BCPS, AAHIVP
Princy N Kumar
Princy N Kumar, MD, FIDSA, MACP
Jeffrey Kwong
Jeffrey Kwong, DNP, MPH, AGPCNP-BC, FAANP, FAAN, AAHIVS, ACRN
Neha Sheth Pandit
Neha Sheth Pandit, PharmD, AAHIVP, BCPS
Nimish Patel
Nimish Patel, PharmD, PhD, AAHIVP

Activity

Progress
1
Course Completed

In this episode, Brooke Bates, PharmD, BCPS, AAHIVP, and Neha Sheth Pandit, PharmD, AAHIVP, BCPS, discuss the most clinically relevant studies on HIV adverse events presented at IAS 2023, including:

  • REPRIEVE study of pitavastatin for cardiovascular prevention in people living with HIV at low to moderate cardiovascular risk
  • Data on weight change with switch from integrase inhibitor–based ART to doravirine/islatravir in the P017 and P018 studies
  • DEFINE study evaluating weight change after a switch to DRV/COBI/FTC/TAF in people living with HIV who experienced weight gain with integrase inhibitor–based ART